Eisai

89

$80.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (+0.01%) As of 8:31 AM EDT pre-market
+$0.01 (+0.01%) Pre-Market

Why Robinhood?

You can buy or sell Eisai and other stocks, options, ETFs, and crypto commission-free!

About ESALY

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. Read More The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan. ESALY is listed on the Pink Current market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).

Employees
10,998
Headquarters
Tokyo, Tokyo
Founded
1936
Market Cap
23.00B
Price-Earnings Ratio
20.60
Dividend Yield
1.66
Average Volume
2.14K
High Today
$80.22
Low Today
$80.21
Open Price
$80.22
Volume
30.00
52 Week High
$90.82
52 Week Low
$48.52

Collections

ESALY News

BenzingaJul 13

Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease

TOKYO, July 14, 2020 - (JCN Newswire) - The Alzheimer's Clinical Trials Consortium (ACTC), Eisai Co., Ltd., and Biogen Inc. announced today that a new Phase III
0
BenzingaJul 12

Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded

Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120 TOKYO, July 13, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that i
0
BenzingaJul 9

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Eisai Co., Ltd. Public Relations: +81-(0)3-3817-5120 Merck & Co., Inc., Kenilworth, N.J., U.S.A. Media Relations Pamela Eisele: (267) 305-3558 Michael Close: (2
0

You May Also Like

Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.